Search

Your search keyword '"K. Haustermans"' showing total 487 results

Search Constraints

Start Over You searched for: Author "K. Haustermans" Remove constraint Author: "K. Haustermans"
487 results on '"K. Haustermans"'

Search Results

1. Patients’ needs in proton therapy: A survey among ten European facilities

5. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

8. OC-0511 Urethra and bladder dose-effect relations for genitourinary toxicity after EBRT for prostate cancer

12. PH-0328 Current practice for selection of adult patients for proton therapy across Europe

14. OC-0631 Proton and photon treatment planning comparison for oesophageal cancer between six European centres

15. PD-0818 Dose prediction with deep learning: the effect of data quality and quantity in the model’s accuracy

16. PD-0881 Deep learning dose prediction as a tool to evaluate treatment complications based on NTCP models

17. Radiotherapie bij primaire prostaatkanker: als minder meer wordt

20. Which patients should be still considered for late salvage radiotherapy for rising or persistently elevated PSA after radical prostatectomy: Results from a large multi-institutional study

21. PO-1437 Endocrine Late- Effects after Childhood and Adolescent Cancer - The Pan-European Registry HARMONIC

23. Five-Year Toxicity after EBRT for Localized Prostate Cancer with or without a Simultaneously Integrated Focal Boost up to 95Gy: Results of a Randomized Controlled Trial

24. PO-1591: Dosimetric accuracy of beam gating, MLC tracking and couch tracking to manage prostate rotation

25. PH-0114: Dose-volume effects for GI toxicity following EBRT for prostate cancer in the FLAME trial

26. OC-0612: The FLAME trial: benefit of a focal boost for prostate cancer on biochemical disease-free survival

27. OC-0315: Quality of life after EBRT with or without focal boost for prostate cancer in the FLAME trial

28. 68Ga-PSMA-11-PET, 18F-PSMA-1007-PET and MRI for Gross Tumor Volume Delineation in Primary Prostate Cancer: Intermodality and Inter-tracer Variability

31. Which Margin Should Be Added to the GTV?

32. When Should IGRT Be Done?

34. There is no way to compensate for a non-timely use of salvage radiation therapy in men with recurrent prostate cancer after radical prostatectomy

35. EP-1556 The effect of an endorectal balloon on GI toxicity after EBRT for localized prostate cancer

37. OC-0510 MRI radiomics to predict tumour response in patients with locally advanced rectal cancer

38. OC-0160 When PI-RADS and ISUP meet each other: identification of candidates for pelvic lymph node dissection

39. OC-0380 Dose response relation in esophageal cancer after neoadjuvant therapy: multi-institutional analysis

40. What is the best definition of biochemical response to salvage radiation therapy in prostate cancer patients treated for PSA rising after radical prostatectomy? Results from a multi-institutional series

41. Assessing the impact and predictors of other-cause mortality in patients treated with post-prostatectomy salvage radiation therapy in order to avoid possible overtreatment: Results from a large, multi-institutional study

43. Effect of hospital volume on quality of care and outcome after rectal cancer surgery

44. Correlation between the location of the index tumour and the location of positive lymph nodes in high-risk prostate cancer. A monocentric positive lymph node mapping study

45. PV-0100: Impact of lung dose on postoperative complications after trimodality treatment in esophageal cancer

48. EP-2144: Tumor and OAR delineation variation – Dice coefficient versus dose assessed with automated planning

Catalog

Books, media, physical & digital resources